William G. Wierda, MD, PhD, on Pirtobrutinib in Treatment-Naive Patients With CLL/SLL
ASCO 2026
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 is comparing pirtobrutinib to bendamustine plus rituximab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); BRUIN CLL-314 is comparing pirtobrutinib to ibrutinib in the same patient population (Abstract 7044).
The ASCO Post Staff
Jame Abraham, MD, FACP, of Cleveland Clinic, provides an update on the DESTINY-Breast05 trial, which is an ongoing phase III trial investigating postneoadjuvant trastuzumab deruxtecan (T-DXd) as compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with residual invasive disease and node-positive disease at surgery or inoperable disease at diagnosis. Dr. Abraham makes special note of rates of interstitial lung disease seen in the trial and methods of management.
The ASCO Post Staff
Jennifer J. Knox, MD, FRCPC, of Princess Margaret Cancer Centre, provides expert commentary on a phase III study of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic cancer (Abstract LBA5).
The ASCO Post Staff
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced breast cancer with emergent ESR1 mutations. Earlier reports from the trial showed improved progression-free survival with the SERD (Abstract LBA1007).
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have been pretreated with Bruton tyrosine kinase covalent inhibitors (Abstract TPS7100).
For more information about the trial, visit ClinicalTrials.gov (identifier NCT07342478).
Dai Chihara, MD, of The University of Texas MD Anderson Cancer Center, reviews results from an open-label, single-arm, phase II trial that investigated the combination of epcoritamab with R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) classified as unfit or frail per geriatric assessment or not eligible for anthracycline chemotherapy due to reduced ejection function or prior exposure (Abstract 7002).
